杂志简称：j clin pharmacol
中文译名：《临床药理学杂志》
收录属性：scie（2024版）, 目次收录（维普）,英文期刊,
自引率：5.80%
投稿方向：医学、pharmacology & pharmacy 药学
SCI/E期刊基本信息
出版周期：月刊 地区：美国
中科院分区：3区
是否TOP：非TOP期刊
是否综述：非综述期刊
是否OA：非OA期刊
国际标准刊号：ISSN0091-2700；EISSN1552-4604
杂志语言：英语
出版国家：美国
杂志官网 联系方式
出版地址：SAGE PUBLICATIONS INC,2455 TELLER RD,THOUSAND OAKS,USA,CA,91320
杂志邮箱：
投稿网址：http://mc.manuscriptcentral.com/jocp
杂志官方网址：https://accp1.onlinelibrary.wiley.com/journal/15524604
出版商网址：http://www.wiley.com/WileyCDA/
杂志投稿要求
投稿须知【杂志社官方网站信息】
Author Guidelines
Instructions for Authors
Please visit The Journal of Clinical Pharmacology at http://accp1.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)1552-4604/author-guidelines.html to reach these instructions at any time.
For guidance on how to prepare, write and submit a manuscript to any journal, please follow this link: http://www.mpip-initiative.org/mpip-authorship-activities/authors-submission-toolkit
Page Charges: JCP has no page charges for publication.
Please Note: These instructions must be followed for manuscript submission to JCP. Manuscripts will be returned without review if the instructions are not followed.
Editorial Content
JCP is a publication dedicated to clinical (human) pharmacology. Manuscripts are invited that deal with the effects of drugs in humans. Animal research and in vitro research without direct human applicability will not be considered. These include, but are not limited to, the general categories of pharmacokinetics (PK) and drug disposition, drug metabolism, pharmacodynamics (PD), clinical trials and design issues, pharmacogenomics and pharmacogenetics, pharmacometrics and population PK/PD, pharmacoepidemiology, pharmacovigilence, and human pharmacology. In addition, another area of emphasis for submissions is the validation and use of biomarkers in drug development. Articles should be clearly written and well organized. Priority will be given to new developments in the field along with manuscripts dealing with PK/PD relationships of drug response in humans.
Types of Papers (The limits should be strictly followed)
Original Research Papers (Full Manuscript)
These may be up to 6500 words, 8 tables/figures total and up to 150 references. An unstructured abstract is required.
Original Research Papers (Brief Report)
These may be up to 3250 words, 4 tables/figures total and up to 75 references. An unstructured abstract is required.
Reviews
Both narrative and systematic reviews are considered for publication. All narrative reviews must critically evaluate the literature and should not cite other reviews in the reference list. Reviews that are just a restatement of the literature will be rejected. Additionally, all reviews must have tables and/or figures and not be solely text. Reviews may be up to 7000 words, 10 tables/figures total, and up to 200 references. An unstructured abstract is required.
Reporting on Meta-Analyses
All meta-analyses to be published in the Journal should have clear objectives regarding drug effects and be based on thorough, systematic and recent review of the literature. Usually, a meta-analysis is done to determine the general and more specific effects on the basis of various small or large studies investigating the same research questions. The search strategy, selection process and statistical methods used should be described in detail in the manuscript. Beyond the type and design of selected studies, authors should provide details on exposure regarding the drug(s) to be examined, i.e., substance, dose, route of administration, and duration of treatment. Relevant patient characteristics, e.g.,. demographics, disease state and co-medication, should be described in sufficient detail. Meta-analysis of clinical trials should be accompanied by the PRISMA flow diagram and checklist (LIberati et al., PLoS Med. 2009 Jul 21;6(7):e1000100), those of observational studies of clinical trials should be accompanied by the MOOSE checklist (Stroup et al., JAMA. 2000; 283(15):2008-12). The preferred length of meta-analyses is as described above for original research papers. Extensive tables on the characteristics of included or excluded studies should be submitted as Electronic Supplementary Material (ESM) (for detailed information on ESM see also Electronic Supplementary Material in the Instructions for Authors) and will be published online only. Meta-analyses reports should follow the guidelines for Full Manuscript Original Research Papers.